Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis

Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis

Abstract Clinical success of IL-17/IL-23 pathway biologics for the treatment of moderate to severe psoriasis suggests that targeting RORγt, a master regulator for the proliferation and function of Th17 cells, could be an effective alternative. However, oral RORγ antagonists (VTP43742, TAK828) with h...

Full description

Bibliographic Details
Main Authors: Suxing Liu, Dong Liu, Ru Shen, Di Li, Qiyue Hu, Yinfa Yan, Jiakang Sun, Fengqi Zhang, Hong Wan, Ping Dong, Jun Feng, Rumin Zhang, Jing Li, Lianshan Zhang, Weikang Tao
Format: Article
Language:English
Published: Nature Portfolio 2021-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-88492-1

Internet

https://doi.org/10.1038/s41598-021-88492-1

Similar Items